OpGen, Inc. (NASDAQ:OPGN) is reporting second quarter earnings results on Wednesday 12th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.51 per share.
For the full year, analysts predict revenues of $ 6.82 million, while looking forward to loss of $ 1.66 per share.
Previous Quarter Performance
OpGen, Inc. came out with loss for the first quarter of $ 0.43 per share, from the revenue of $ 0.62 million. The quarterly revenues lowered 43.64 percent compared with the same quarter last year. Street analysts expected OpGen, Inc. to report loss of $ 0.39 per share on revenue of $ 0.60 million for the first quarter. The bottom line results missed street analysts by $ 0.04 or 10.26 percent, at the same time, top line results outshined analysts by $ 0.02 million or 3.33 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of OpGen, Inc.
Stock Performance
According to the previous trading day, closing price of OPGN was $ 2.56, representing a 178.26 % increase from the 52 week low of $ 0.92 and a 80 % decrease over the 52 week high of $ 12.80.
The company has a market capital of $ 39.58 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”OPGN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
OpGen, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.opgen.com
OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
